(MENAFN- ProactiveInvestors)
Limited () has some interesting news on the horizon in the form of results in its human clinical trial.
The ASX has granted the company a trading halt to prepare with its shares placed in pre-open.
Last week the company announced that it has completed the treatment of two canine patients with PPL-1 in combination with Carboplatin one of the “standard of care” chemotherapy drugs used in both human and veterinary anticancer medicine.
Neither dog suffered any adverse events despite the fact they both had progressive advanced cancers and few treatment options.
The halt will last until the earlier of an announcement being made to the market or the opening of trade on Friday 24th July 2015.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.